Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Celularity ( (CELU) ) has shared an announcement.
On August 13, 2025, Celularity Inc. entered into an asset purchase agreement with Celeniv Pte. Ltd., selling certain intellectual property for $33,812,230, which was used to retire all senior secured debt. The agreement included a license back of the IP to Celularity with a five-year repurchase option. This restructuring eliminated $41.6 million in debt, improved financial flexibility, and led to the creation of four wholly-owned subsidiaries to enhance operational efficiency across its commercial units.
The most recent analyst rating on (CELU) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.
Spark’s Take on CELU Stock
According to Spark, TipRanks’ AI Analyst, CELU is a Neutral.
The stock’s overall score is driven by strong technical momentum, despite weak financial performance and unattractive valuation. The company’s high leverage and negative cash flows are areas of concern, but recent price momentum indicates investor interest.
To see Spark’s full report on CELU stock, click here.
More about Celularity
Celularity Inc. is a regenerative and cellular medicine company focused on developing, manufacturing, and commercializing advanced biomaterial products and cell therapies derived from the postpartum placenta. The company targets age-related and degenerative diseases by leveraging the unique biology of the placenta to address cellular senescence, chronic inflammation, and tissue degeneration.
Average Trading Volume: 236,743
Technical Sentiment Signal: Buy
Current Market Cap: $83.34M
See more data about CELU stock on TipRanks’ Stock Analysis page.